Korro Bio Inc (KRRO) Stock AnalysisKRROKorro Bio Inc

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Korro Bio Inc is not a strong buy at the current price of $12.91 due to its recent performance and financial metrics. The stock has a Relative Strength Index (RSI) of 42.055, indicating it is nearing oversold territory, but it has also seen a significant decline of 41.86% over the past year. While analysts have set price targets ranging from $15 to $23, the company reported a quarterly EPS loss of $1.07, which is concerning. The main risk is the negative net income, which reached -50,042,000 USD in Q4 2025, suggesting ongoing financial challenges.